|
Actelion to end setipiprant clinical development in asthma, allergic rhinitis
RTT News PK: News ) on Monday said two recently concluded studies with the first orally-active CRTH2 antagonist, setipiprant, in asthma and seasonal allergic rhinitis did not confirm efficacy findings made in earlier studies. Accordingly, the company is … Actelion provides update on CRTH2 program |
View full post on asthma – Google News